cam1615SS1 / GT Biopharma - LARVOL DELTA

A tri-specific killer engager against mesothelin targets NK cells towards lung cancer. (PubMed, Front Immunol) - "Importantly, TriKE triggered NK cell responses from patients at all stages of disease and treatment, suggesting TriKE can enhance current therapies. These pre-clinical studies suggest mesothelin-targeted TriKE has the potential to overcome the immunosuppressive environment of NSCLC to treat disease."

Journal • Trispecific • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD14 • IL15 • MSLN

Tri-specific killer engagers target natural killer cells towards mesothelioma (SITC 2022) - "Conclusions GTB-5550 drove NK cell responses towards all mesothelioma subtypes, while cam1615SS1 successfully targeted epithelial peritoneal mesothelioma. In future studies we aim to combine TriKE with immune checkpoint inhibitors to test their potential to drive innate immune responses in the context of currently approved therapies."

IO biomarker • Lung Cancer • Malignant Pleural Mesothelioma • Mesothelioma • Oncology • Sarcoma • Solid Tumor • CD276 • IFNG • IL15 • MSLN

GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting (GlobeNewswire) - "GT Biopharma...will present two poster presentations at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022)....TriKEs cam1615SSS1 and GTB-5550 were tested across multiple mesothelioma cell lines in particular cell lines that were present in pleural and peritoneal lines. TriKEs targeting mesothelin or B7H3 induce NK cell degranulation and cytokine production and in the presence of cam1615SSS1 or GTB-5550, NK cells control peritoneal mesothelioma in three-dimensional spheroid cultures."

Preclinical • Lung Cancer • Mesothelioma • Oncology • Solid Tumor • Thoracic Cancer

GT Biopharma Presented Preclinical Data Demonstrating Novel Mesothelin-Targeted TriKE Driving Cytotoxicity Across All Stages of Non-Small Cell Lung Cancer at ESMO TAT 2022 (PRNewswire) - "GT Biopharma...presented preclinical data demonstrating its novel TriKE driving NK cell immunotherapy against non-small cell lung cancer (NSCLC) in the hypoxic solid tumor microenvironment at ESMO's Targeted Anticancer Therapies Congress (TAT)....Results suggest that mesothelin-targeted TriKE can work alongside current standard of care and provide benefit even in the hypoxic environment of a solid tumor."

Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer